Literature DB >> 32417912

Circulating CD19+CD24hiCD38hi regulatory B cells as biomarkers of response to methotrexate in early rheumatoid arthritis.

Paula Fortea-Gordo1, Alejandro Villalba1, Laura Nuño1, María José Santos-Bórnez1, Diana Peiteado1, Irene Monjo1, Amaya Puig-Kröger2, Paloma Sánchez-Mateos2, Emilio Martín-Mola1, Alejandro Balsa1, María-Eugenia Miranda-Carús1.   

Abstract

OBJECTIVE: The protagonism of regulatory B cells seems to vary along the course of the disease in murine models of inflammatory conditions. Decreased numbers of circulating regulatory CD19+CD24hiCD38hi transitional (cTr) B cells have been described in patients with long-standing RA, thus our objective was to examine the frequency and evolution of cTr B cells in the peripheral blood of early RA (ERA) patients.
METHODS: Freshly isolated peripheral blood mononuclear cells from 48 steroid- and DMARD-naïve ERA patients with a disease duration of <24 weeks and 48 healthy controls (HCs) were examined by flow cytometry. Co-cultures of isolated memory B cells were established with autologous T cells in the absence or presence of Tr B cells.
RESULTS: As compared with HCs, ERA patients demonstrated an increased frequency of cTr B cells. cTr B cells of ERA patients and HCs displayed an anti-inflammatory cytokine profile and were able to downregulate T cell IFN-γ and IL-21 production, together with ACPA secretion in autologous B/T cell co-cultures. Basal frequencies of cTr B cells above the median value observed in HCs were associated with a good EULAR response to MTX at 12 months [relative risk 2.91 (95% CI 1.37, 6.47)]. A significant reduction of cTr B cells was observed 12 months after initiating MTX, when the cTr B cell frequency was no longer elevated but decreased, and this was independent of the degree of clinical response or the intake of prednisone.
CONCLUSION: An increased frequency of regulatory cTr B cells is apparent in untreated ERA and the baseline cTr B cell frequency is associated with the clinical response to MTX at 12 months.
© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  B cells; cytokines; early rheumatoid arthritis; methotrexate

Mesh:

Substances:

Year:  2020        PMID: 32417912     DOI: 10.1093/rheumatology/keaa186

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  4 in total

Review 1.  B Cells and Antibodies as Targets of Therapeutic Intervention in Neuromyelitis Optica Spectrum Disorders.

Authors:  Jan Traub; Leila Husseini; Martin S Weber
Journal:  Pharmaceuticals (Basel)       Date:  2021-01-06

Review 2.  Advances of Regulatory B Cells in Autoimmune Diseases.

Authors:  Qiugang Zhu; Ke Rui; Shengjun Wang; Jie Tian
Journal:  Front Immunol       Date:  2021-04-15       Impact factor: 7.561

Review 3.  B Cells in Rheumatoid Arthritis:Pathogenic Mechanisms and Treatment Prospects.

Authors:  Fengping Wu; Jinfang Gao; Jie Kang; Xuexue Wang; Qing Niu; Jiaxi Liu; Liyun Zhang
Journal:  Front Immunol       Date:  2021-09-28       Impact factor: 7.561

4.  Remission Induced by TNF Inhibitors Plus Methotrexate is Associated With Changes in Peripheral Naïve B Cells in Patients With Rheumatoid Arthritis.

Authors:  Borja Hernández-Breijo; Chamaida Plasencia-Rodríguez; Victoria Navarro-Compán; Carlota García-Hoz; Israel Nieto-Gañán; Cristina Sobrino; Javier Bachiller-Corral; Mariana Díaz-Almirón; Ana Martínez-Feito; Teresa Jurado; Paloma Lapuente-Suanzes; Gema Bonilla; Cristina Pijoán-Moratalla; Garbiñe Roy; Mónica Vázquez-Díaz; Alejandro Balsa; Luisa M Villar; Dora Pascual-Salcedo; Eulalia Rodríguez-Martín
Journal:  Front Med (Lausanne)       Date:  2021-06-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.